- Insitro is an AI-driven biotechnology company focused on transforming drug discovery and development through machine learning and data integration, positioning itself as a leader in the metabolism, oncology, and neuroscience therapeutic areas.
- In January 2026, Insitro announced its acquisition of CombinAbleAI to enhance its AI platform for drug discovery, launching the TherML™ platform which integrates various drug modalities into a single AI engine.
- Insitro has expanded its collaboration with Bristol Myers Squibb to include additional therapeutic targets for ALS, leveraging its AI-driven Virtual Human™ platform to identify key biological drivers.
- Insitro's ideal buyers are pharmaceutical companies and biotech firms seeking to accelerate drug development and reduce late-stage risks, particularly those interested in innovative solutions for complex diseases using AI technology.
Engineering is the largest team with 168 employees, representing roughly 56% of the workforce. Supporting functions include Business Management (31), Finance and Administration (22), Human Resources (16), Information Technology (16), Healthcare (13), and Operations (12). Go‑to‑market and product functions are smaller by comparison, with Marketing and Product (8) and Sales and Support (4), alongside 11 employees categorized as Other. This mix underscores a strong technical focus supported by core business and operational teams.
Insitro’s largest hub is San Francisco, CA, with 136 employees—about 45% of the company. A sizable share of the team is also captured under Other (96), reflecting additional distributed locations. The company maintains a notable Bay Area footprint beyond San Francisco, including South San Francisco (21), Redwood City (9), San Jose (7), Palo Alto (6), and San Mateo (6). Additional presence includes New York, NY (9), Boston, MA (6), and San Diego, CA (5), indicating a primarily California‑based workforce with select teams in other U.S. cities.
